AbbVie’s tight grip on Humira market raises concerns about biosimilars By Reuters Stocks June 7, 2024 By Patrick Wingrove (Reuters) – AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing…
Boehringer to lay off salespeople as Humira biosimilar sales lag By Reuters Stocks April 4, 2024 By Patrick Wingrove (Reuters) – Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to…